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Background: Lipoprotein lipase (LPL) plays a central role in triglyceride-rich lipoproteinmetabolismby catalyzing
the hydrolysis of triglycerides. Quantiﬁcation of serum LPL is useful for diagnosing lipid disorders, but there is no
rapid method of measuring LPL for clinical use.
Methods:We developed a rapid and sensitive latex particle-enhanced turbidimetric immunoassay (LTIA) serum
LPL using latex bead-immobilized anti-LPL monoclonal antibodies. The assay was performed on a Hitachi 7700 P
analyzer and evaluated for its validity as a method of quantitating the serum LPL concentration in parallel with
ELISA.
Results:Dilution tests using LTIA produced a calibration curve from0.5 to 800 ng/ml.Within-run CVwas obtained
in the range of 2.2–5.5%. No interference was observed in the testing of specimens containing potentially inter-
fering substances such as bilirubin-F and C, hemoglobin, triglycerides and rheumatoid factor. A strong correlation
between LTIA and ELISA was conﬁrmed (n = 40, r = 0.967, y=0.99x-1.86). The normal range of LPL in pre-
heparin serum was 50–77 ng/ml and in post-heparin plasma 354–410 ng/ml, respectively.
Conclusion: The LTIA assay is applicable in quantitating the concentration of LPL in both pre-heparin serum and
post-heparin plasma. This assay is more convenient and faster than ELISA and highly suitable for clinical routine
analysis.© 2015 Elsevier B.V. All rights reserved.1. Introduction
Lipoprotein lipase (LPL) plays a major role in the metabolism and
transport of lipids and lipoproteins [1,2]. It is the enzyme responsible
for the hydrolysis of core triglycerides (TG) in chylomicrons (CM) and
very low density lipoproteins (VLDL), producing CM remnants and
VLDL remnants, respectively. Determination of LPL in plasma has typi-
cally been routinely carried out by ELISA after the intravenous injection
of heparin (with its activity and concentration). However, it is also
known that a comparatively high LPL concentration (ranging approxi-
mately 30–100 ng/ml in normal controls) is found in the pre-heparinLaboratory Medicine, Gunma
-machi, Maebashi, Gunma 371-
kami).serum,with an undetectable level of LPL activity, indicating that thema-
jority of circulating LPL is catalytically inactive, but still a ligand for the
receptors [3–6].
The LPL concentration and activity in the post-heparin plasma have
been clinically used for the detection of LPL deﬁciency [2], but in general
not for the diagnosis of lipid disorders or the risk of cardiovascular
disease. This is because heparin injection dissociates LPL from the
blood vessel endothelium, so the result does not necessarily reﬂect the
physiological or pathophysiological concentration of circulating LPL.
An LPL-ELISA assay using speciﬁcmonoclonal antibodieswas report-
edly developed previously by Brunzell et al. [7] and Ikeda et al. [8] for
the detection of LPL in human plasma, which involved the administra-
tion of a heparin injection to the patients before the measurement of
the plasma LPL concentration. Considering the assay time and the tech-
nical steps required for the quantitative measurement by ELISA, this
method is not suitable for large-scale epidemiological studies or routine
clinical laboratory assay.
Fig. 1. Linearity of LTIA. Linearity tests of LPL were performed using LTIA on a H7700 P
analyzer. Two calibrators for the LPL concentrations are shown for the pre-heparin
serum (Fig. 1A) and post-heparin plasma (Fig. 1B).
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assay for the LPL concentration that has both good sensitivity and good
calibrator stability, in particular if the measurement of the pre-heparin
serum LPL concentration is going to be clinically meaningful and useful.
LPL concentrations in the pre-heparin serum have been intensively in-
vestigated by Shirai and his colleagues the last decades using LPL-ELISA,
revealing the clinical signiﬁcance of the pre-heparin LPL concentration
in cardiovascular and diabetic diseases [9–16].
We recently showed the possibility that the LPL concentration in
the pre-heparin serum is replaceable with the LPL activity in the post-Table 1
Within-assay precision.
Low
32.0
Mid
100.0
High
280.0
1 28.6 93.5 279.4
2 29.7 97.5 280.4
3 30.4 97.6 291.2
4 31.7 97.7 286.1
5 30.7 93.4 296.2
6 28.8 91.5 293.6
7 29.7 95.6 293.2
8 27.3 98.3 293.2
9 26.8 96.3 284.6
10 27.5 97.2 295.8
Mean (ng/ml) 29.1 95.9 289.4
S.D. (ng/ml) 1.60 2.30 6.25
CV (%) 5.5 2.4 2.2heparin plasma based on a comparison between them [17]. Therefore,
the measurement of the LPL concentration in the pre-heparin serum
will be able to provide more practical clinical applications in TG-rich
patients without the need of a heparin injection using an automated
LPL assay. As the serum pre-heparin LPL concentration is sufﬁciently
high so as to measure it with a latex assay system, we developed a
rapid and sensitive latex particle-enhanced turbidimetric immunoassay
(LTIA) using latex bead-immobilized LPL-speciﬁc antibodies. The per-
formance of the LTIA was evaluated on a Hitachi H7700 P automated
analyzer. We compared its analytical properties with a commercially
available ELISA assay [18] in normal volunteers, with and without hep-
arin injection.
2. Materials and methods
2.1. Reagents
Polystyrene latex particles were obtained from Fujikura Corporation
and bovine serum albumin (BSA) from Sigma, respectively. Interfering
reagents, containing bilirubin F and C, hemoglobin, triglycerides and
rheumatoid factor, were from Sysmex. All of the chemicals and reagents
were of the highest available grade.
2.2. Preparation of blood samples
The study was conducted in relatively healthy young volunteers
(some were overweight or obese) in a male (n = 19) and female
(n = 21) population (Caucasian 25, Asian 5, Hispanic 4, African
American 3, others 3) with a median age of 24 years and BMI of 24 at
the University of California, Davis, USA. All of the volunteers were
injected with heparin (50 unit/kg BW) for the LPL activity assays [19].
The University of California at Davis Institutional Review Board ap-
proved the experimental protocol and the subjects providedwritten in-
formed consent to participate in the study. Two hundred forty healthy
volunteers (male = 170, female = 70, median age of 26 years and me-
dian BMI of 21.6) were recruited at Tenshi College (Sapporo, Japan),
with obtained written informed consent and University Ethical Com-
mittee approval [20].
The prepared serum was used for the experiments on precision,
sensitivity, cross-reactivity, dilution and recovery as well as the normal
range of healthy controls.Fig. 2. Analytical detection limit estimated as the concentration equal to the mean
absorbance of 10 replicates of the zero calibrator plus 2.6.
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The anti-LPL antibodies were raised against human recombinant LPL
at Immuno-Biological Lab. The globulin fraction of 2 anti-LPL monoclo-
nal antibodies (57A5 and 88B8) in mouse ascites was isolated using
Protein-G Sepharose (GE Healthcare) and eluted with a 0.1 mol/l citrate
buffer (pH2.5), thendialyzedwith PBS. The protein concentration of the
antibodies was estimated by the optical density.
2.4. Preparation of the latex-immobilized antibody reagent
An optimization of the assay reagent was performed on the basis of
other latex labeled immunoassays [19]. The diameter of the polystyrene
latex bead and the amount of the antibody for immobilization were
modiﬁed. In a preliminary study we conﬁrmed that the particle volume
has a major inﬂuence on the assay range and the amount of antibody
used for immobilization contributes to the sensitivity of the assay. To
adjust for the range of LPL in serum, we utilized 0.3 μm latex particles.Fig. 3. InterferePolystyrene latex beads (100 mg; mean diameter 0.2 μm) were
suspended in 1 ml of 0.01 mol/l HEPES buffer (pH 7.0). Nine milliliters
(0.5 mg/ml) and 1 ml of 10% (wt/vol) polystyrene latex beads were
incubated in 0.01 mol/l HEPES buffer (pH 7.0) for 1 h at 37 °C followed
by the addition of 0.01 mol/l HEPES buffer (pH 7.0) containing 0.5% BSA
at a ratio of 3 volumes to 2 volumes of latex bead suspension. After 1 h,
antibody­immobilized latex beadswerewashed twice by centrifugation
and then re-suspended in 10ml of 0.01mol/l HEPES buffer (pH7.0). The
suspension of the immobilized latex beads was stored at 4 °C and used
as a reagent for measurement of LPL.
2.5. Calibrator preparation
In-house calibrators for LPL measurement were prepared with
the recombinant LPL generated by CHO cells at IBL (Fujioka, Japan) in
Tris–HCl buffer (pH 8.0). To determine the values on the in-house cali-
brator, calibrators from Sekisui Medical ELISA with known concentra-
tions, were used for comparison.nce tests.
Fig. 4. Correlation between LTIA and ELISA for LPL. (A and B). The ﬁgure shows the results of regression analysis on the measured serum LPL concentrations between LTLIA (y-axis) and
ELISA (x). Fig. 4A shows the data in the lower concentration scale (b150 ng/ml) and Fig. 4B the data in the higher concentration scale (b600 ng/ml). Bland–Altman plots show the differ-
ence between the LTIA readings and ELISA readings at different ambient LPL levels at Fig. 4A&B, respectively. The x-axis shows themeans of 2 readings and the y-axis shows the difference
between the 2methods. The dashed line represents the 95% conﬁdence limits of the differences. A regression line is shown on the graph demonstrating that themean difference between
the methods is small and that there is no consistent preference between the methods.
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Sample processing pipetting steps and measurements were
performed automatically on a Hitachi H7700 P automated analyzer
(Hitachi Instruments Engineering). Brieﬂy, 4 μl serum and 160 μl of
reagent 1 (0.01 mol/l HEPES buffer (pH 7.0)) were injected into the
reaction cuvette. After 5 min of incubation at 37 °C, 54 μl of reagent 2
(antibody­immobilized latex bead suspension in 0.01mol/l HEPES buff-
er (pH 7.0)was added to the cuvette to start the turbidimetric immuno-
reaction. After another 5min, the LPL concentrationwas calculated from
the difference in the absorbance values between the two time points
(the absorbance at 5 and 10 min) with a primary wavelength of
800 nm. The calibration curve was obtained with a series of working
LPL calibrators and a six-point calibration curve was used to calculate
the values of the serum samples. Measurement by ELISAwas performed
using an LPL ELISA kit (Sekisui Medical, Tokyo).2.7. Statistical analysis
All analyses were executed with the Dr. SPSS II package (SPSS Inc.).
The data are presented asmedian values, with 25th and 75th percentile
values, rather than as mean values with standard deviations, because
the LPL concentration was not normally distributed. Pearson's correla-
tion coefﬁcientwas calculated between LTIA and ELISA. Univariate anal-
ysis was performed between LPL and TG, HDL-C, LDL-C, RLP-C, sd LDL-C
and apolipoprotein CIII. The correlation between LPL and the above lipidparameters was evaluated by Spearman's correlation coefﬁcient. A
p b 0.05 was considered statistically signiﬁcant.3. Results
3.1. Linearity
Six concentrations of recombinant LPL (0, 50, 100, 200, 400 and
800 ng/ml) were used to assess the calibration curve. After dilution
(up to 10 times) with saline, serial dilutions were measured with
three replicates per specimen and the linearity was evaluated. Within
the measuring range of 0–200 ng/ml and 0–800 ng/ml, the deviations
from theoretical values did not exceed 5%, indicating no lack of parallel-
ism and showing good linearity (Fig. 1A and B). These results suggest a
good linearity within both the low (up to 150 ng/ml) and high (up to
800 ng/ml) range.3.2. Precision
To determine the precision of the LTIA, we performed a replication
study, as shown in Table 1. Three pooled plasma samples were
aliquoted into 1.5 ml plastic tubes for each concentration and frozen
at−70 °C.We analyzed 3 samples in 10 runs within a day with a single
calibration. As shown in Table 1, the within-run CV was 5.5% for
32 ng/ml, 2.4% for 100 ng/ml and 2.2% for 280 ng/ml.
n = 40
median = 50.3
n = 40
median = 381
A
B
Fig. 5.Histogram of the LPL concentration in healthy volunteers (USA) in the pre-heparin
serum (Fig. 5A) and post-heparin plasma (Fig. 5B). Therewas no distribution difference in
the LPL concentration between males and females. The median and 25% tile 75% tile (RI;
reference interval) values of the LPL concentration are shown. The post-heparin LPL con-
centration was signiﬁcantly higher than that in the pre-heparin concentration.
n = 240
median =  57.7
49.3 67.2 ng/mL
Fig. 6.Histogramof the LPL concentration in healthy volunteers (Japan) in the pre-heparin
serum. There was no distribution difference of LPL concentration between males and
females. The median and 25% tile to 75% tile (RI; reference interval) values of the LPL
concentration are shown.
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Fig. 2 shows the analytical detection limit estimated as the concen-
tration equal to themean absorbance of 10 replicates of the zero calibra-
tor plus 2.6 SD. The detection limit of the assay was 10.7 ng/mlTable 2
The univariate correlation coefﬁcient analysis between the LPL concentration and the lipid
parameters.3.4. Carry-over
Wemeasured the saline after themeasurement of the samples with
a high concentration of LPL (400ng/ml). Therewas no detectable sign of
carry-over of LPL on a Hitachi 7700 P.Analyte rs p
Triglyceride −0.237 0.0003
LDL cholesterol 0.0908 NS
HDL cholesterol 0.3659 b0.0001
RLP cholesterol −0.1909 0.0036
Small, dense LDL cholesterol 0.0242 NS
Apolipoprotein C-III 0.0961 NS3.5. Stability of LPL in plasma
There was no signiﬁcant difference between the fresh samples and
the conserved analytes measured after 2 days at 4 °C, or in terms of
freeze thaw cycles, showing a good stability of LPL (details not shown).These results were in agreement with the results determined using
ELISA [18].
3.6. Interference
Interference tests were performed by adding potentially interfering
substances to serum pools and examining any changes in the ab-
sorbance values (Fig. 3). We investigated the effects of free bilirubin F
and C, hemoglobin, triglyceride and rheumatoid factor on the measure-
ment of LPL. The results showed that bilirubin F and C up to 200mg/l did
not affect the assay precision. Similarly, hemoglobin up to 5 g/l, triglyc-
eride up to 1500 fonnazin turbidity units (FTU) and rheumatoid factor
up to 500 IU/ml did not alter the assay precision. The recovery of LPL
was within 10% of the original concentration (data not shown). These
results suggest that the substances tested here do not interfere with
the ability of the assay to measure LPL accurately.
3.7. Correlation of LTIA and ELISA
For comparison of the LTIA and LPL assayswith the established ELISA
assay (Sekisui Medical), blood samples were analyzed by two different
range calibrators in both the pre-heparin serum and post-heparin
plasma. As shown in Fig. 4A, regression statistics calculated in the tested
sera (n=40) gave y(LTIA)=0.845x(ELISA)+4.433, r=0.965. Even in a
relative high range in post-heparin plasma (Fig. 4B), using an LPL value
between 0 and 600 ng/ml (n=40), the correlation result was y(LTIA)=
0.871x(ELISA)+10.114, r = 0.942, indicating a good correlation be-
tween the two methods. A Bland–Altman plot was constructed to visu-
alize the differences between the twomethods [21]. The difference plot
conﬁrmed that there was a difference between the values measured
with LTIA and ELISA, and the 95% conﬁdence limits of the difference
135T. Machida et al. / Clinica Chimica Acta 442 (2015) 130–135were±13 ng/ml and±31 ng/ml, respectively. Themean difference be-
tween the two immunoassays was 6.8 ng/ml and 45 ng/ml at these
levels, suggesting that there was no consistent bias between the two
methods. A somewhat greater variance was seen at an LPL level
N300 ng/ml. This was not considered to reduce the reliability or poten-
tial usefulness of the assay, since the potential interest regarding risk as-
sessment lies in the low range.
3.8. Plasma LPL concentrations in healthy volunteers
Themedian pre-heparin serum LPL (Fig. 5A) and post-heparin plasma
LPL (Fig. 5B) concentration in 40 healthy US volunteers in the fasting state
were 50.3 ng/ml (range 50–77ng/ml (25% tile to 75% tile)) and 381ng/ml
(range 354–411 ng/ml (25% tile to 75% tile)), respectively. The median
pre-heparin LPL concentration in 240 healthy Japanese subjects (170
male, 70 female aged 20–72 years) in fasting state was 57.7 ng/ml
(range 49–67 ng/ml (25% tile to 75% tile)) (Fig. 6).
No signiﬁcant difference in the LPL concentration was detected
between the serum and EDTA plasma specimens. Table 2 shows the
univariate correlation coefﬁcient analysis among the lipid parameters.
LPL is signiﬁcantly and positively correlated with HDL-C and inversely
correlated with TG and RLP-C (Table 2).
4. Discussion
Themain purpose for the development of the LPL latex assay system
was to determine the pre-heparin serum LPL concentration for routine
clinical laboratory use in a manner that does not require heparin injec-
tion before bloodwithdrawal. Heparin injection has been a great barrier
for the determination of LPL in clinical practice. Although LPL in the pre-
heparin serum is known to not have any activity, its concentration is
high enough to be detected by a latex assay system as well as by
ELISA. To the best of our knowledge, this is the ﬁrst report of the deter-
mination of the serum LPL concentrationwith a latex assay system. This
system provides a rapid and sensitive LPL assay for routine clinical prac-
tice and may be applied to large epidemiological studies using frozen
samples.
In order to determine the pre-heparin LPL concentration in ordinary
clinical laboratories,wehavedeveloped a latex particle-enhanced turbidi-
metric immunoassay (LTIA) for the measurement of LPL concentration
over a wide range in both the pre-heparin serum and post-heparin plas-
ma, and compared the result with an ELISA assay currently in use [18].
The assay presented here takes only 10 min on an automated analyzer.
Intra-assay CVs of the ELISA were in the range of 2.2–5.5%. Therefore,
the superior reproducibility of our results adds further value to this conve-
nient assay system. Therefore, the monitoring of a low range of LPL, even
less than 10ng/ml, seems to be available for clinical use. The analytical de-
tection limit of this assay was 10.7 ng/ml and is thus available for the de-
tection of hyperlipidemic serum. This value is equal to the reported lower
detection limit of ELISA. In respect to the precision and analysis time, the
LTIA assay is superior to the ELISA assay and highly correlated with the
automated LPL activity assay in post-heparin plasma reported by
Imamura et al. (data not shown) [22].
The reproducibility, simplicity and full automation capacity with a
widely used clinical chemistry analyzer like the Hitachi 7700 P are the
key to routine clinical diagnosis. The LTIA assay offers the advantages
of being precise, easy to perform and more rapid than the ELISA test
as an adiponectin latex assay system [23].
The post-heparin LPL concentrations were 5 to 10 fold higher than
pre-heparin LPL, but the pre-heparin LPL concentrations by LTIA were
the levels within the range of accurate measurement. Also, in healthy
Japanese subjects, the pre-heparin LPL concentration was inversely
correlated with TG and RLP-C, and positively correlated with HDL-C,
which are the same results shown by LPL-ELISA assay [18].The measurement of the pre-heparin LPL concentration may prove
to be clinicallymeaningful, because it is possible to identify LPL deﬁcien-
cy cases, such as type IV and V with a high TG concentration, without
any need of a heparin injection.
In conclusion, this study has shown that the latex particle-enhanced
turbidimetric immunoassay evaluated here is highly correlated with
LPL-ELISA. It is a robust, easily implemented tool for measuring LPL
concentrations in the clinical laboratory without the need of a heparin
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